

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY

**CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
Bristol-Myers Squibb Company		09/24/2009	CORPORATION: DELAWARE

**RECEIVING PARTY DATA**

Name:	Forest Laboratories, Inc.
Street Address:	909 Third Avenue
City:	New York
State/Country:	NEW YORK
Postal Code:	10022
Entity Type:	CORPORATION: DELAWARE

**PROPERTY NUMBERS Total: 1**

Property Type	Number	Word Mark
Registration Number:	1415548	FLUMADINE

**CORRESPONDENCE DATA**

Fax Number: (212)308-8582  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
 Phone: 212-593-2112  
 Email: madis48@earthlink.net  
 Correspondent Name: Christopher Serbagi  
 Address Line 1: 488 Madison Avenue  
 Address Line 2: Suite 1120  
 Address Line 4: New York, NEW YORK 10022

NAME OF SUBMITTER:	Christopher Serbagi
Signature:	/christopher Serbagi/
Date:	10/06/2009

Total Attachments: 1

**900144745**

**TRADEMARK  
 REEL: 004074 FRAME: 0474**

OP \$40.00 1415548





Bristol-Myers Squibb Company

345 Park Avenue New York, NY 10154

September 24, 2009

Forest Laboratories, Inc.  
909 Third Avenue  
New York, New York 10022

Attn: Eric Agovino, Esq.

Re: U.S. Reg. No. 1,415,548 for FLUMADINE

Dear Mr. Agovino:


Bristol-Myers Squibb ("BMS") is the successor in interest to certain assets of DuPont Merck Pharmaceutical Co. ("DuPont").

At one time, DuPont was the owner of U.S. Reg. No. 1,415,548 for the trademark FLUMADINE (the "Registration"). According to the records of the U.S. Patent and Trademark Office ("USPTO"), DuPont acquired the Registration on or about February 13, 1992, and assigned the Registration to Forest Laboratories, Inc. ("Forest") on or about July 23, 1992.

Forest has advised that pursuant to a certain "Notice of Security in Trademark" Agreement dated as August 31, 1992 ("Security Interest") between DuPont and Forest, Forest granted a security interest to DuPont in the Registration. DuPont recorded the Security Interest with the USPTO on October 1, 1992, at Reel 0895, Frame 0536.

To the extent that BMS acquired any right or interest in the trademark FLUMADINE or the Registration as a result of the transactions that caused BMS to become the successor in interest to certain assets of DuPont, this is to confirm that BMS has no continuing interest in this trademark or the Registration.

This is further to confirm that BMS has no objection to Forest filing and recording a document with the USPTO that results in the expungement of the Security Interest from the record for the Registration maintained by the USPTO. Forest may submit this letter to the USPTO in support of such a filing.

Very truly yours,  
  
Nadine P. Flynn